Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
- None.
- None.
The agreement between Avenue Therapeutics and the FDA on the Phase 3 safety study protocol for IV tramadol signifies a pivotal step in the drug's development process. The focus on opioid-induced respiratory depression is of paramount importance, as this is a critical safety concern with opioid use. The non-inferiority study design aims to demonstrate that IV tramadol is not worse than the standard treatment, IV morphine, by a specified margin when it comes to inducing respiratory depression. This is crucial as the opioid crisis has heightened the need for safer pain management options.
From a research perspective, the use of a bunionectomy patient model is noteworthy. This surgical model has already provided positive safety and efficacy data for IV tramadol in previous trials, which may bode well for the outcome of this study. However, it is essential to consider that the effectiveness and safety in one surgical model may not directly translate to all post-operative pain scenarios. The composite primary endpoint will provide a robust measure of respiratory safety, but the study's success will hinge on the balance between efficacy and safety.
For stakeholders, the timeline is critical. With the potential to complete the study within 12 months, there is a clear path to addressing the Complete Response Letter (CRL) from the FDA. A positive outcome could lead to FDA approval, which would be a significant catalyst for Avenue's stock. However, the mention of the need for financing indicates a potential future dilution of shares or the introduction of a strategic partner, which could affect shareholder value.
The strategic implications of Avenue's announcement are multifaceted. The company's stock price may respond positively to the news of an agreed-upon Phase 3 trial protocol with the FDA, as it reduces regulatory uncertainty. However, investors should be mindful of the inherent risks associated with clinical trials. The successful completion of this trial is a prerequisite for the drug's approval and any setbacks could adversely affect the company's valuation.
Furthermore, the company's statement regarding the necessity of additional financing or a strategic partnership to initiate the Phase 3 safety study introduces a degree of financial uncertainty. The source and terms of financing will be crucial, as they may have a dilutive effect on current shareholders or impact the company's financial flexibility. A partnership could bring in non-dilutive capital and expertise but may also come with trade-offs such as shared profits or milestones payments.
A positive outcome from the trial could significantly enhance Avenue's market position, offering an alternative to traditional opioids for post-operative pain management. The potential approval of IV tramadol could open up a sizeable market opportunity, given the ongoing efforts to find safer pain management options amidst the opioid epidemic. This would likely lead to an upward revaluation of Avenue's stock, provided the market conditions are favorable and the company successfully navigates the commercialization process.
The advancement of IV tramadol into the final stages of clinical testing is an indication of Avenue's commitment to addressing a significant unmet need in pain management. The market for post-operative pain management is substantial and the introduction of a new therapy could disrupt the current treatment landscape, which is heavily reliant on opioids. Given the societal push towards reducing opioid use, a new drug like IV tramadol could be well-received by both the medical community and patients seeking safer alternatives.
The competitive landscape must be considered, as the approval of IV tramadol could position Avenue against established opioid and non-opioid pain medications. The drug's safety profile, particularly regarding opioid-induced respiratory depression, will be a critical factor in its market penetration. Should the safety study yield positive results, Avenue could leverage this data in its marketing and sales strategy to gain a competitive edge.
Long-term implications for stakeholders include the potential for Avenue to capture market share from competitors, provided the drug's efficacy and safety are validated. The company's ability to execute on commercialization strategies post-approval will determine the actual impact on the market. Additionally, the outcome of this study will likely influence investor sentiment and could affect Avenue's ability to secure future financing on favorable terms.
MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it has reached final agreement with the U.S. Food and Drug Administration (“FDA”) on the Phase 3 safety study protocol and statistical analysis approach, including the primary endpoint, for intravenous (IV) tramadol, which is in development for the treatment of acute post-operative pain in a medically supervised setting. The final non-inferiority study is designed to assess the theoretical risk of opioid-induced respiratory depression related to opioid stacking on IV tramadol compared to IV morphine.
“We have worked collaboratively with the FDA over the last year to design a study that will address a theoretical safety risk. We are pleased with the agreed-upon plan for the clinical trial and believe that this trial will support a safe profile for IV tramadol administration for acute pain in the post-operative period,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
The study will randomize approximately 300 post bunionectomy patients to IV tramadol or IV morphine for pain relief administered during a 48-hour post-operative period. Of note, IV tramadol demonstrated safety and efficacy in this same surgical model in two Phase 3 efficacy trials. Patients will have access to IV hydromorphone, a Schedule II opioid, for rescue of breakthrough pain. The primary endpoint is a composite of elements indicative of respiratory depression. Avenue believes the study can be completed within 12 months and submitted to the FDA to address the CRL and potentially lead to approval of IV tramadol.
Dr. MacLean continued, “Subject to obtaining the necessary financing, which could be provided through a strategic partnership, Avenue plans to initiate the Phase 3 safety study as soon as possible, and could potentially have study results in-hand as early as the end of this year. We expect that a positive study outcome could result in the FDA approval of IV tramadol, potentially improving the current treatment paradigm available for U.S. patients in managing post-operative pain and providing significant near-term value for Avenue shareholders.”
About Avenue Therapeutics
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER101, an oral small molecule selective GABAA α2/3 receptor positive allosteric modulator for CNS diseases, and IV tramadol, which is in Phase 3 clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.
Forward-Looking Statements
This press release contains predictive or “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this press release, including statements that express our intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “should,” “would” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations, estimates and projections made by management about our business, our industry and other conditions affecting our financial condition, results of operations or business prospects. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties. Factors that could cause such outcomes and results to differ include, but are not limited to, risks and uncertainties arising from: expectations for increases or decreases in expenses; expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidate or any other products we may acquire or in-license; our use of clinical research centers and other contractors; expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities; expectations for generating revenue or becoming profitable on a sustained basis; expectations or ability to enter into marketing and other partnership agreements; expectations or ability to enter into product acquisition and in-licensing transactions; expectations or ability to build our own commercial infrastructure to manufacture, market and sell our product candidates; acceptance of our products by doctors, patients or payors; our ability to compete against other companies and research institutions; our ability to secure adequate protection for our intellectual property; our ability to attract and retain key personnel; availability of reimbursement for our products; estimates of the sufficiency of our existing cash and cash equivalents and investments to finance our operating requirements, including expectations regarding the value and liquidity of our investments; the volatility of our stock price; expected losses; expectations for future capital requirements; and those risks discussed in our filings which we make with the SEC. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.
Contact:
Jaclyn Jaffe
Avenue Therapeutics, Inc.
(781) 652-4500
ir@avenuetx.com
FAQ
What is the company name and ticker symbol mentioned in the press release?
What is the purpose of the Phase 3 safety study protocol mentioned in the press release?
What is the primary endpoint of the study mentioned in the press release?
How many patients will be randomized for the study mentioned in the press release?
What is the potential outcome of a positive study result mentioned in the press release?
